Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(®)): Its Clinical Usefulness and Future Vistas

por Shirasaka, Tetsuhiko
Publicado 2009

Pharmacokinetic Modulation of Plasma 5‐Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5‐Fluorouracil

por Fujii, Setsuro, Fukushima, Masakazu, Shimamoto, Yuji, Shirasaka, Tetsuhiko
Publicado 1989

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

por Kobayashi, Kazuma, Tsuji, Akihito, Morita, Sojiro, Horimi, Tadashi, Shirasaka, Tetsuhiko, Kanematsu, Takashi
Publicado 2006

Antitumor Activity of BOF‐A2, a New 5‐Fluorouracil Derivative

por Fujii, Setsuro, Fukushima, Masakazu, Shimamoto, Yuji, Ohshimo, Hideyuki, Imaoka, Takeshi, Shirasaka, Tetsuhiko
Publicado 1989

Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sa...

por Fujii, Setsuro, Shimamoto, Yuji, Ohshimo, Hideyuki, Imaoka, Takeshi, Motoyama, Masaaki, Fukushima, Masakazu, Shirasaka, Tetsuhiko
Publicado 1989

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)

por Tanaka, Hiroaki, Kanda, Mitsuro, Morita, Satoshi, Taguri, Masataka, Nishikawa, Kazuhiro, Shimada, Mitsuo, Muguruma, Kazuya, Koeda, Keisuke, Takahashi, Masazumi, Nakamori, Mikihito, Konno, Hiroyuki, Tsuji, Akihito, Hosoya, Yoshinori, Shirasaka, Tetsuhiko, Yamamitsu, Susumu, Sowa, Michio, Kitajima, Masaki, Okajima, Masazumi, Kobayashi, Michiya, Sakamoto, Junichi, Saji, Shigetoyo, Hirakawa, Kosei
Publicado 2017